Work Here?
About Elegen
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$35M
Headquarters
San Carlos, California
Founded
2017
Overview
Elegen focuses on improving the DNA manufacturing process within the synthetic biology sector. The company provides custom DNA synthesis services to researchers, biotech companies, and pharmaceutical firms that need high-quality synthetic DNA for applications like biomanufacturing and mRNA-based treatments. Elegen uses advanced technologies to ensure fast turnaround times and high accuracy in DNA synthesis, which are essential for its clients' projects. Unlike many competitors, Elegen not only streamlines traditional DNA manufacturing workflows but also enables the production of valuable biologics and small molecules. The company's goal is to support the growing bioeconomy by facilitating the development of next-generation therapeutics, including mRNA medicines.
Simplify's Take
What believers are saying
- Elegen raised $35M to expand its ENFINIA DNA product line for clinical development.
- Partnerships with companies like GSK enhance Elegen's market reach and credibility.
- The synthetic biology market's 28.8% CAGR offers growth opportunities for Elegen.
What critics are saying
- Competition from Twist Bioscience and Ginkgo Bioworks threatens Elegen's market share.
- Supply chain vulnerabilities in microfluidic components could disrupt Elegen's production.
- Regulatory challenges in biomanufacturing may increase compliance costs for Elegen.
What makes Elegen unique
- Elegen's ENFINIA platform offers rapid synthesis of highly complex DNA in 10 days.
- The company specializes in cell-free DNA manufacturing, reducing contamination risks.
- Elegen's microfluidic technology enhances efficiency and accuracy in DNA synthesis.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$35M
Meets
Industry Average
Funded Over
1 Rounds
Andreessen HorowitzIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Short Term Disability
Long Term Disability
Parental Leave
Commuter Benefits
Fitness Allowance
Learning Allowance
Growth & Insights and Company News
6 month growth
ā 5%1 year growth
ā 4%2 year growth
ā 2%Elegen, the leader in next-generation cell-free DNA manufacturing, announced the early access launch of ENFINIA IVT Ready DNA.
IDT lengthens DNA offerings with Elegen partnership.
Elegen, a San Carlos, CA-based DNA synthesis company, raised $35M in Series B funding led by Triatomic Capital, with participation from GSK, John Ballantyne, and existing investors including Andreessen Horowitz. Peter Zhou of Triatomic Capital will join Elegenās board. The funds will be used to expand the ENFINIAā¢ DNA product line for clinical development of genetic medicines. CEO Matthew Hill aims to accelerate DNA synthesis and streamline new clinical modalities.
Elegen, a San Carlos, CA-based company which specialises in DNA synthesis and production, raised $35M in Series B funding.
Elegen has raised $35 million in a Series B funding round led by Triatomic Capital, with participation from GSK, John Ballantyne, and existing investors like Andreessen Horowitz and Agilent Technologies. The funds will be used to expand Elegenās ENFINIAā¢ DNA product line and enhance its microfluidics approach for clinical workflows. Peter Zhou from Triatomic Capital will join Elegenās board. CEO Matthew Hill emphasized the investment's role in advancing DNA synthesis technology.
There are no jobs for Elegen right now.
Find jobs on Simplify and start your career today
About Elegen
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$35M
Headquarters
San Carlos, California
Founded
2017
There are no jobs for Elegen right now.
Find jobs on Simplify and start your career today